Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TATEN
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
- NCT04251169 ↗
- Terminated
- SOLTI Breast Cancer Research Group
- Focused
We haven't built an HCP commentary report on TATEN (pembrolizumab plus paclitaxel in HR+/HER2- non-luminal advanced breast cancer after CDK4/6-inhibitor progression) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TATEN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Metastatic Breast Cancer
- Interventions
- Pembrolizumab; Paclitaxel
- Arms
- Pembrolizumab + Paclitaxel · Experimental
- Enrollment
- 20
- Primary outcomes
- Overall Response Rate of Pembrolizumab in Combination With Paclitaxel in HR+/HER2- Non-luminal Subtype Advanced Breast Cancer Defined by the PAM50 Assay
- Sponsor
- SOLTI Breast Cancer Research Group with Merck Sharp & Dohme LLC
- Start
- Jul 21, 2020
- Primary completion
- Apr 10, 2024
- Results posted
- Yes
- Registry record
- NCT04251169 · updated Jun 3, 2025